找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Cancer Drug Safety and Public Health Policy; A Changing Landscape Charles Bennett,Courtney Lubaczewski,Bartlett With Book 2022 The Editor(s

[复制链接]
楼主: DART
发表于 2025-3-26 23:00:00 | 显示全部楼层
发表于 2025-3-27 04:43:46 | 显示全部楼层
Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions ArAdverse drug/device reactions (ADRs) serious enough to lead to box warnings on drug labels or drug withdrawals occur in about one fifth of all new molecular entities.
发表于 2025-3-27 09:08:59 | 显示全部楼层
Moderna, Pfizer-BioNTech, and Johnson & Johnson/Janssen Post-Covid Vaccine Hematological Adverse EvThe Centers for Disease Control (CDC) indicated in 2021 that it would monitor for possible post-COVID-19 vaccination coagulopathy adverse events (AEs).
发表于 2025-3-27 12:15:39 | 显示全部楼层
发表于 2025-3-27 14:47:01 | 显示全部楼层
发表于 2025-3-27 19:57:59 | 显示全部楼层
发表于 2025-3-27 23:35:05 | 显示全部楼层
https://doi.org/10.1007/978-3-540-87866-7of Hemorrhagic and Thrombotic Complications of Pharmaceuticals to the U.S. Food and Drug Administration: Empirical Findings for Warfarin, Clopidogrel, Ticlopidine, and Thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38(08):905–907. .). Prevailing opinion
发表于 2025-3-28 03:38:24 | 显示全部楼层
Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions,usly approved) biological agents (Kozlowski et al. in N Engl J Med 365:385–388, 2011). The biological epoetin accounts for $1.8 billion in drug spending annually worldwide (primarily for the treatment of anemia due to chronic kidney disease or anemia due to cancer chemotherapy.)
发表于 2025-3-28 08:58:32 | 显示全部楼层
7楼
发表于 2025-3-28 10:56:17 | 显示全部楼层
7楼
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-24 18:15
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表